We are live on ! Find out more
XBIT icon

XBiotech
XBIT

41 hedge funds and large institutions have $5.48M invested in XBiotech in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,400% more call options, than puts

Call options by funds: $45K | Put options by funds: $3K

2.1% less ownership

Funds ownership: 9.63% → 7.53% (-2.1%)

15% less funds holding

Funds holding: 48 → 41 (-7)

30% less capital invested

Capital invested by funds: $7.81M → $5.48M (-$2.32M)

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

53% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 17

Holders
41
Holders Change
-7
Holders Change %
-14.58%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
8
Reduced
17
Closed
8
Calls
$45K
Puts
$3K
Net Calls
+$42K
Net Calls Change
+$45K

Top Buyers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
+$461K
2
Morgan Stanley
Morgan Stanley
New York
+$103K
3
BCM
Bridgeway Capital Management
Texas
+$74K
4
Jane Street
Jane Street
New York
+$34.4K
5
PAP
Persistent Asset Partners
Hong Kong
+$33.4K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$1.28M
2
Millennium Management
Millennium Management
New York
-$693K
3
Citadel Advisors
Citadel Advisors
Florida
-$106K
4
HF
HRT Financial
New York
-$69K
5
BlackRock
BlackRock
New York
-$33.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
TNB
26
Thomasville National Bank
Georgia
$31.9K – – –
PFPG
27
Pinnacle Financial Partners (Georgia)
Georgia
$28.2K +$29.1K +11,796 New
TSS
28
Two Sigma Securities
New York
$24.8K +$25.6K +10,378 New
UBS Group
29
UBS Group
Switzerland
$12.1K -$3.51K -1,422 -22%
JP Morgan Chase
30
JP Morgan Chase
New York
$2.69K -$3.09K -1,254 -53%
RhumbLine Advisers
31
RhumbLine Advisers
Massachusetts
$2.22K – – –
ME
32
McIlrath & Eck
Washington
$1.8K – – –
Fidelity Investments
33
Fidelity Investments
Massachusetts
$1.08K +$345 +140 +45%
Jones Financial Companies
34
Jones Financial Companies
Missouri
$884 – – –
Simplex Trading
35
Simplex Trading
Illinois
$160 -$629 -255 -79%
LFG
36
Larson Financial Group
Missouri
$50 – – –
Optiver Holding
37
Optiver Holding
Netherlands
$19 – – –
Barclays
38
Barclays
United Kingdom
$2 -$508 -206 -100%
SS
39
SBI Securities
Japan
$2 – – –
Citadel Advisors
40
Citadel Advisors
Florida
– -$106K -42,816 Closed
HF
41
HRT Financial
New York
– -$69K -26,156 Closed
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
– -$6.33K -2,569 -93%
Carson Wealth (CWM LLC)
43
Carson Wealth (CWM LLC)
Nebraska
– -$256 -104 -82%
AAP
44
Arax Advisory Partners
Colorado
– -$58 -22 Closed
EWA
45
EverSource Wealth Advisors
Alabama
– -$45 -17 Closed
EP
46
Essential Partners
California
– -$43 -16 Closed
Citigroup
47
Citigroup
New York
– -$32 -12 Closed
TWD
48
True Wealth Design
Ohio
– -$8 -3 Closed
SS
49
Sunbelt Securities
Texas
– -$5 -2 Closed
1
2

XBIT Hedge Fund Activity: Q4 2025 in Review

41 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q4 2025, worth a combined $5.48M — down 30% from $7.81M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of XBIT and 4 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 8 added.

The largest buyer was Ameriprise, opening a new position worth an estimated $461K. The largest seller was Vanguard Group, cutting an estimated $1.28M.

  • 41 institutional investors held XBiotech (XBIT) as of Q4 2025, down from 48 in Q3 2025.
  • Funds reported $5.48M of XBiotech stock for Q4 2025, down 30% quarter-over-quarter.
  • 4 funds opened new XBiotech positions in Q4 2025 and 8 closed out, a net change of -4 holders.
  • The largest XBiotech buyer in Q4 2025 was Ameriprise, an estimated $461K added.
  • The largest XBiotech seller in Q4 2025 was Vanguard Group, an estimated $1.28M sold.

Based on aggregated 13F filings for Q4 2025.